Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2022.02.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria.
J Allergy Clin Immunol Glob
February 2025
Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, Ohio.
Background: Omalizumab (OMA), a recombinant humanized IgG monoclonal anti-IgE antibody, is approved for treatment for chronic spontaneous urticaria (CSU) refractory to second-generation H-antihistamine (SGAH) therapy. However, currently, there are no validated serum biomarkers to reliably predict response to OMA treatment.
Objective: We explored the real-world clinical utility of using serum biomarkers for predicting response to OMA for CSU patients with disease refractory to high-dose SGAH therapy.
Comparison of the characteristics of patients with chronic urticaria receiving standard- or high-dose omalizumab.
Eur Ann Allergy Clin Immunol
January 2025
Division of Allergy and Clinical Immunology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
In patients whose chronic urticaria (CU) cannot be controlled with omalizumab 300 mg and antihistamines, the dose can be increased up to 600 mg. The study aimed to compare the clinical characteristics of patients receiving 300 mg versus higher doses of omalizumab, and to evaluate baseline predictors for updosing. A total of 159 patients who have been followed up at a tertiary care allergy center and received omalizumab for at least 12 months were included.
View Article and Find Full Text PDFDistinct Clinical Profiles of IgE and IgG Autoantibodies to Thyroid Peroxidase in Chronic Spontaneous Urticaria.
Allergy Asthma Immunol Res
November 2024
Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Purpose: In chronic spontaneous urticaria (CSU), autoimmune thyroid disease is the most common autoimmune comorbidity, and many CSU patients have immunoglobulin (Ig)E or IgG autoantibodies to thyroid peroxidase (TPO). It remains unclear how anti-TPO IgE and IgG autoantibodies are linked to each other and are associated with CSU features, activity, and therapeutic responses.
Methods: CSU patients (n = 146, 92 females, mean age 42.
High prevalence of long COVID in anti-TPO positive euthyroid individuals with strongly elevated SARS-CoV-2-specific T cell responses and moderately raised anti-spike IgG levels 23 months post-infection.
Front Immunol
October 2024
Department of Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
Introduction: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), causes post-acute infection syndrome in a surprisingly large number of cases worldwide. This condition, also known as long COVID or post-acute sequelae of COVID-19, is characterized by extremely complex symptoms and pathology. There is a growing consensus that this condition is a consequence of virus-induced immune activation and the inflammatory cascade, with its prolonged duration caused by a persistent virus reservoir.
View Article and Find Full Text PDFArticle Synopsis
- The Basophil Activation Test (BAT) is identified as a key biomarker for predicting autoimmune chronic spontaneous urticaria (aiCSU), but its real-world application and relation to omalizumab therapy are still under-researched.
- A study conducted between 2010 and 2024 analyzed the clinical and laboratory characteristics of patients with chronic spontaneous urticaria (CSU) based on their BAT results, collecting data on various biomarkers and treatment responses.
- Results showed that BAT positive patients exhibited specific traits such as low IgE levels and higher positivity for markers like anti-thyroid peroxidase; notably, these patients experienced shorter effectiveness of omalizumab treatment, highlighting the importance of BAT in clinical settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!